Systemic lupus erythematosus disease activity index 2000 responder index 50: Sensitivity to response at 6 and 12 months

Rheumatology (United Kingdom)

Volumn 51, Issue 10, 2012, Pages 1814-1819

  Touma, Zahi ^a   Urowitz, Murray B ^a   Taghavi Zadeh, Shahrzad ^a   Ibañez, Dominique ^a   Gladman, Dafna D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Lupus disease activity; Outcome measures; SLEDAI 2K; SRI; SRI 50

Indexed keywords

ANTIMALARIAL AGENT; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; ARTICLE; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS RESPONDER INDEX; TREATMENT RESPONSE;

ADULT; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDNISONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84867122366     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes146     Document Type: Article

References (15)

1. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
2. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
3. Touma Z, Urowitz MB, Ibañez D, Gladman DD. SLEDAI-2K days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus 2011;20:67-70.
4. Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus 2010;19:49-51.
5. Touma Z, Gladman DD, Ibañez D, Urowitz MB. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol 2011;38:275-84.
6. Touma Z, Urowitz MB, Fortin R et al. Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity. J Rheumatol 2011;38:868-73.
7. Furie RA, Petri MA, Wallace DJ et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
8. Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase trial. Lancet 2011;377:721-31.
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40: 1725.
10. Hay EM, Bacon PA, Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86:447-58.
11. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996; 55:756-60.
12. Isenberg DA, Gordon C. From BILAG to BLIPS-disease activity assessment in lupus past, present and future. Lupus 2000;9:651-4.
13. Petri M, Kim MY, Kalunian KC et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
14. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000;27:377-9.
15. Touma Z, Gladman DD, Ibañez D, Taghavi-Zadeh S, Urowitz MB. SLEDAI-2K Responder Index-50 (SRI-50) enhances the ability of SLE Responder Index (SRI) to identify responders in clinical trials. J Rheumatol 2011;38: 2395-9.